CN115715291A - 布鲁顿酪氨酸激酶抑制剂及其制备方法 - Google Patents

布鲁顿酪氨酸激酶抑制剂及其制备方法 Download PDF

Info

Publication number
CN115715291A
CN115715291A CN202180035678.1A CN202180035678A CN115715291A CN 115715291 A CN115715291 A CN 115715291A CN 202180035678 A CN202180035678 A CN 202180035678A CN 115715291 A CN115715291 A CN 115715291A
Authority
CN
China
Prior art keywords
methyl
pyridin
dimethyl
pyrrolo
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180035678.1A
Other languages
English (en)
Inventor
许忻
陈嘉
王贯
张林丽
蒋青云
奚丞昊
孙康
张小娟
陈春桥
李帅
李强
夏良泽
王影
夏小二
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Huahai Pharmaceutical Co Ltd
Shanghai Synergy Pharmaceutical Sciences Co Ltd
Original Assignee
Zhejiang Huahai Pharmaceutical Co Ltd
Shanghai Synergy Pharmaceutical Sciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Huahai Pharmaceutical Co Ltd, Shanghai Synergy Pharmaceutical Sciences Co Ltd filed Critical Zhejiang Huahai Pharmaceutical Co Ltd
Publication of CN115715291A publication Critical patent/CN115715291A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

一类布鲁顿酪氨酸激酶抑制剂及其制备方法和在医药领域的应用，所述布鲁顿酪氨酸激酶抑制剂可用于预防和/或治疗与布鲁顿酪氨酸激酶介导的相关疾病，如自身免疫性疾病、癌症或炎症类疾病等。所提供的化合物，经实验研究，其对布鲁顿酪氨酸激酶靶点的选择性高，体内动物实验能表现出优异的药效作用。

Description

PCT国内申请，说明书已公开。

Claims (12)

  1. PCT国内申请，权利要求书已公开。
CN202180035678.1A 2020-06-18 2021-06-18 布鲁顿酪氨酸激酶抑制剂及其制备方法 Pending CN115715291A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010558345 2020-06-18
CN2020105583454 2020-06-18
PCT/CN2021/100901 WO2021254483A1 (zh) 2020-06-18 2021-06-18 布鲁顿酪氨酸激酶抑制剂及其制备方法

Publications (1)

Publication Number Publication Date
CN115715291A true CN115715291A (zh) 2023-02-24

Family

ID=79268506

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180035678.1A Pending CN115715291A (zh) 2020-06-18 2021-06-18 布鲁顿酪氨酸激酶抑制剂及其制备方法

Country Status (3)

Country Link
US (1) US20230348471A1 (zh)
CN (1) CN115715291A (zh)
WO (1) WO2021254483A1 (zh)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103038233A (zh) * 2010-05-07 2013-04-10 吉利德康涅狄格有限公司 吡啶酮和氮杂吡啶酮化合物及使用方法
CN104024255A (zh) * 2011-11-03 2014-09-03 霍夫曼-拉罗奇有限公司 作为btk活性的抑制剂的烷基化哌嗪化合物
CN104105697A (zh) * 2011-11-03 2014-10-15 霍夫曼-拉罗奇有限公司 二环哌嗪化合物
CN104125959A (zh) * 2011-11-03 2014-10-29 霍夫曼-拉罗奇有限公司 作为btk活性的抑制剂的杂芳基吡啶酮和氮杂-吡啶酮化合物
CN110446710A (zh) * 2016-12-15 2019-11-12 豪夫迈·罗氏有限公司 制备btk抑制剂的方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103038233A (zh) * 2010-05-07 2013-04-10 吉利德康涅狄格有限公司 吡啶酮和氮杂吡啶酮化合物及使用方法
CN104024255A (zh) * 2011-11-03 2014-09-03 霍夫曼-拉罗奇有限公司 作为btk活性的抑制剂的烷基化哌嗪化合物
CN104105697A (zh) * 2011-11-03 2014-10-15 霍夫曼-拉罗奇有限公司 二环哌嗪化合物
CN104125959A (zh) * 2011-11-03 2014-10-29 霍夫曼-拉罗奇有限公司 作为btk活性的抑制剂的杂芳基吡啶酮和氮杂-吡啶酮化合物
CN110446710A (zh) * 2016-12-15 2019-11-12 豪夫迈·罗氏有限公司 制备btk抑制剂的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JAMES J. CRAWFORD 等: "Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development", 《JOURNAL OF MEDICINAL CHEMISTRY》, vol. 61, no. 6, 19 February 2018 (2018-02-19), pages 2227 - 2245, XP055685494, DOI: 10.1021/acs.jmedchem.7b01712 *

Also Published As

Publication number Publication date
US20230348471A1 (en) 2023-11-02
WO2021254483A1 (zh) 2021-12-23

Similar Documents

Publication Publication Date Title
ES2957233T3 (es) Inhibidores de quinasa tipo receptor de activina
CN111902417B (zh) 一种二芳基巨环化合物、药物组合物以及其用途
CN107922417B (zh) 蝶啶酮衍生物作为egfr抑制剂的应用
US20220259235A1 (en) EGFR Inhibitor, Composition, and Preparation Method Therefor
CN112020496B (zh) 作为rho激酶抑制剂的苯并吡唑类化合物
JP2019521980A (ja) Ｊａｋ阻害剤としてのピロロピリミジン化合物の結晶
CN116888108B (zh) 新型egfr降解剂
WO2015058661A1 (zh) Bcr-abl激酶抑制剂及其应用
KR20190021345A (ko) Egfr 저해제로 제공되는 아닐린 피리미딘 화합물의 결정
KR20200013702A (ko) α7니코틴성 아세틸콜린 수용체의 리간드 화합물 및 그 응용
CA2952230C (en) Pyrimidine compounds and methods using the same
CN116102535A (zh) 一种含氮化合物、其制备方法及应用
CN111989332B (zh) 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用
CN113248497B (zh) 用作fgfr4抑制剂的稠环衍生物
CN112513041B (zh) 三环化合物
TW202110848A (zh) 取代的稠合雙環類衍生物、其製備方法及其在醫藥上的應用
JP2022511236A (ja) 置換キナゾリノン誘導体、及びｍＧｌｕＲ４のポジティブアロステリック調節剤としてのその使用
CN114437116A (zh) 杂环化合物及其制备方法、药物组合物和应用
Carrasco et al. Discovery of novel 2, 3, 5-trisubstituted pyridine analogs as potent inhibitors of IL-1β via modulation of the p38 MAPK signaling pathway
CN113214240B (zh) 作为p2x3受体拮抗剂的n-甲酰胺基吡唑啉类衍生物及应用
WO2022100738A1 (zh) 含二并环类衍生物抑制剂自由碱的晶型及其制备方法和应用
WO2022111644A1 (zh) 含氮杂环类衍生物的盐、晶型及其制备方法和应用
CN115715291A (zh) 布鲁顿酪氨酸激酶抑制剂及其制备方法
WO2015014283A1 (zh) 蛋白酪氨酸激酶抑制剂及其应用
WO2022174765A1 (zh) 作为Wee-1抑制剂的稠环化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination